Teva's Credit Rating Upgraded as Growth Strategy Gains Traction
Event summary
- S&P Global Ratings upgraded Teva’s long-term issuer credit rating to ‘BB+’ from ‘BB’, while Moody’s affirmed a B1 rating and revised the outlook to positive from stable.
- Teva’s adjusted leverage has declined to 4.4x as of September 30, 2025, and is expected to fall below 4.25x.
- Moody’s anticipates leverage will decline toward 3.5x within 12–18 months.
- The upgrades follow Teva’s Pivot to Growth strategy, which has driven a return to revenue growth after five years of declines.
The big picture
Teva's credit rating upgrades reflect a broader trend of pharmaceutical companies shifting focus towards higher-margin, innovative products to offset declining generic drug revenues. The company's deleveraging efforts and return to growth demonstrate a potential turnaround after years of challenges related to generic competition and debt burdens. The positive sentiment from ratings agencies suggests a growing confidence in Teva's strategic direction, although significant execution risk remains.
What we're watching
- Execution Risk
- The sustainability of Teva's revenue growth will depend on successful commercialization of branded medicines and biosimilars, which faces inherent development and market access challenges.
- Debt Management
- How Teva manages its debt obligations and achieves the projected leverage ratio of 3.5x will be critical to securing further credit rating improvements.
- Generics Headwinds
- The continued stabilization of Teva’s generics business, despite broader industry pressures, will be a key indicator of the overall effectiveness of the Pivot to Growth strategy.
Related topics